Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 16 and 74 diagnosed with Fabry disease.~* Confirmed mutant form of α-galactosidase A shown to be responsive to migalastat in vitro.~* Participant has never been treated with enzyme replacement therapy (ERT) or has not received ERT for 6 consecutive months or longer before the screening visit for the study.~* Urine GL-3 ≥4 times the upper limit of normal at screening.~* Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for a minimum of 4 weeks before the baseline visit.~* Females who can become pregnant and all males agree to be sexually abstinent or use medically accepted methods of birth control during the study and for 30 days after study completion.~* Participant is willing and able to provide written informed consent and assent, if applicable.~Exclusion Criteria:~* Participant has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis.~* Estimated glomerular filtration rate \<30 milliliters per minute per 1.73 meters squared (chronic kidney disease Stage 4 or 5) based on the Modification of Diet in Renal Disease equation at screening.~* Pregnant or breast-feeding.~* History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol).~* Participant is treated or has been treated with any investigational drug within 30 days of study start.~* Participant is currently treated or has ever been treated with migalastat.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Migalastat (Type: EXPERIMENTAL): Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule taken orally QOD for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).